Stockscreener 앱 받기
40.98
0.04%
0.015
전일 마감가:
$40.97
열려 있는:
$41.05
하루 거래량:
937.75K
Relative Volume:
0.20
시가총액:
$5.25B
수익:
$1.00B
순이익/손실:
$22.39M
주가수익비율:
331.86
EPS:
0.1235
순현금흐름:
$45.01M
1주 성능:
+0.09%
1개월 성능:
+0.87%
6개월 성능:
+107.94%
1년 성능:
+114.36%
1일 변동 폭
$40.95
$41.05
1주일 범위
$40.93
$41.05
52주 변동 폭
$16.10
$41.05
아펠리스 Stock (APLS) Company Profile
명칭
Apellis Pharmaceuticals Inc
전화
617-977-5700
주소
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
40.98 | 5.25B | 1.00B | 22.39M | 45.01M | 0.1235 |
VRTX
Vertex Pharmaceuticals Inc
|
424.60 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
717.55 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.98 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.20 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.11 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
아펠리스 Stock (APLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-13 | 개시 | Roth Capital | Buy |
| 2026-01-28 | 개시 | Barclays | Equal Weight |
| 2026-01-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-11-06 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-15 | 개시 | Wells Fargo | Overweight |
| 2025-09-26 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-09 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-05-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-17 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-11-21 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-10-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-16 | 개시 | William Blair | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Neutral |
| 2024-02-05 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-12-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-02 | 개시 | Mizuho | Neutral |
| 2023-10-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-15 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | 재확인 | Citigroup | Buy |
| 2023-08-03 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-08-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-01-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-19 | 개시 | H.C. Wainwright | Buy |
| 2022-06-17 | 재개 | Stifel | Buy |
| 2022-04-14 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-29 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-09-10 | 재확인 | BMO Capital Markets | Outperform |
| 2021-09-10 | 재확인 | Credit Suisse | Neutral |
| 2021-09-10 | 재확인 | Needham | Buy |
| 2021-09-10 | 재확인 | Oppenheimer | Outperform |
| 2021-09-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-08-19 | 개시 | Jefferies | Buy |
| 2021-08-19 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-16 | 개시 | Goldman | Buy |
| 2020-11-19 | 개시 | Needham | Buy |
| 2020-09-01 | 개시 | Stifel | Buy |
| 2020-07-20 | 개시 | ROTH Capital | Buy |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-04-01 | 개시 | Raymond James | Strong Buy |
| 2020-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-11 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2020-01-07 | 개시 | SVB Leerink | Mkt Perform |
| 2019-12-19 | 개시 | BofA/Merrill | Buy |
| 2019-11-22 | 개시 | Wedbush | Underperform |
| 2019-11-05 | 개시 | Credit Suisse | Neutral |
| 2019-08-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-03-29 | 개시 | Robert W. Baird | Outperform |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-07-30 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-04-12 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
아펠리스 주식(APLS)의 최신 뉴스
Biogen To Buy Apellis; Lilly To Buy Sleep Drug Maker; Nvidia Invests $2 Billion In Marvell |... (c7SV8arzqf) - Fathom Journal
Apellis Pharmaceuticals, Inc. Files Form 8-K with SEC Detailing Company Information and Executive Provisions - Minichart
Top 3 Health Care Stocks That May Collapse This Month - Benzinga
Apellis Updates Executive Separation Plan Amid Biogen Merger - TipRanks
Apellis (APLS) revises executive separation plan tied to Biogen merger - Stock Titan
MSN Money - MSN
Apellis Cell And Gene Update Puts Growth Story In Investor Focus - Sahm
Pictet Asset Management Holding SA Has $9.84 Million Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
UBS Group AG Boosts Stake in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Purchases 49,642 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Jennison Associates LLC Reduces Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis (NASDAQ: APLS) CMO reports bona fide gift of 900 shares - Stock Titan
Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight - GlobeNewswire Inc.
Precision Trading with Apellis Pharmaceuticals Inc. (APLS) Risk Zones - Stock Traders Daily
M&T Bank Corp Has $1.38 Million Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Biogen to acquire Apellis for $5.6B to strengthen immunology portfolio - MSN
APLS stock soars 140% today – here’s everything to know about its massive $5.6B deal with Biogen - MSN
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
Apellis earnings up next: Last report before Biogen takeover? By Investing.com - Investing.com Canada
Biogen Q1 2026 slides: EPS beats forecast, Apellis deal to boost growth - Investing.com
Biogen raised to overweight at Piper Sandler on Apellis buyout - MSN
Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Apellis (APLS) Acquisition to Enhance Biogen's Growth Potential - GuruFocus
Apellis Pharmaceuticals (APLS) Expected to Announce Earnings on Wednesday - MarketBeat
Biogen (NASDAQ: BIIB) boosts profit and cash flow, plans $5.6B Apellis buy - Stock Titan
Apellis deal and Q1 2026 results reshape Biogen (NASDAQ: BIIB) outlook - Stock Titan
Apellis Pharmaceuticals stock hits 52-week high at $40.96 By Investing.com - Investing.com South Africa
Apellis Pharmaceuticals stock hits 52-week high at $40.96 - Investing.com
Apellis surges on $5.6B buyout deal with Biogen - MSN
Apellis (NASDAQ: APLS) outlines 2025 executive pay, board and risk oversight - Stock Titan
Cwm LLC Sells 52,353 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals is the most overbought healthcare stock as Q1 earnings roll on - MSN
APELLIS PHARMACEUTICALS INC (NASDAQ:APLS): A Fitting GARP Opportunity - ChartMill
Why is Apellis Pharmaceuticals (APLS) down 17.3% since last earnings report? - MSN
Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout - MSN
Apellis Pharmaceuticals, Inc. (APLS) surpasses Q4 earnings and revenue estimates - MSN
Cantor Fitzgerald downgrades Apellis Pharmaceuticals (APLS) - MSN
아펠리스 (APLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.78%
3.01%
자본화:
|
볼륨(24시간):